2017 共识声明:临床应用达格列净治疗2型糖尿病

2017-04-27 国外内分泌相关专家小组(统称) Expert Rev Clin Pharmacol. 2017 Apr 21.

本文基于Delphi方法提出了关于达格列净治疗2型糖尿病的临床应用共识,专家指出达格列净科有效降低血糖浓度,具有良好的安全性。其可与其他抗高血糖药物连用,GFR降低可限制其疗效。

中文标题:

2017 共识声明:临床应用达格列净治疗2型糖尿病

英文标题:

A Consensus Statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor Dapagliflozin in patients with type 2 Diabetes Mellitus.

发布日期:

2017-04-27

简要介绍:

本文基于Delphi方法提出了关于达格列净治疗2型糖尿病的临床应用共识,专家指出达格列净科有效降低血糖浓度,具有良好的安全性。其可与其他抗高血糖药物连用,GFR降低可限制其疗效。


拓展指南:糖尿病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2017 共识声明:临床应用达格列净治疗2型糖尿病)] GetToolGuiderByIdResponse(projectId=1, id=461331c001a21814, title=2017 共识声明:临床应用达格列净治疗2型糖尿病, enTitle=A Consensus Statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor Dapagliflozin in patients with type 2 Diabetes Mellitus., guiderFrom=Expert Rev Clin Pharmacol. 2017 Apr 21., authorId=null, author=, summary=本文基于Delphi方法提出了关于达格列净治疗2型糖尿病的临床应用共识,专家指出达格列净科有效降低血糖浓度,具有良好的安全性。其可与其他抗高血糖药物连用,GFR降低可限制其疗效。, cover=, journalId=null, articlesId=null, associationId=949, associationName=国外内分泌相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Thu Apr 27 09:06:26 CST 2017, originalUrl=, linkOutUrl=, content=本文基于Delphi方法提出了关于达格列净治疗2型糖尿病的临床应用共识,专家指出达格列净科有效降低血糖浓度,具有良好的安全性。其可与其他抗高血糖药物连用,GFR降低可限制其疗效。 <div><br> </div> 拓展指南:<strong>与<font color=red>糖尿病</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=461331c001a21814" title="2017 共识声明:临床应用达格列净治疗2型糖尿病" target=_blank>2017 共识声明:临床应用达格列净治疗2型糖尿病</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=689251c001a193fc" title="2017 EURETINA指南:糖尿病黄斑水肿的管理" target=_blank>2017 EURETINA指南:糖尿病黄斑水肿的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=cd3481c001a13eea" title="糖尿病周围神经病变中医临床诊疗指南(2016年版)" target=_blank>糖尿病周围神经病变中医临床诊疗指南(2016年版)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=c28a21c001a085db" title="2017 ABM临床方案#27:胰岛素依赖型糖尿病婴幼儿母乳喂养" target=_blank>2017 ABM临床方案#27:胰岛素依赖型糖尿病婴幼儿母乳喂养</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=374ca1c001a0810d" title="2017 IDF实践指南:糖尿病和斋月" target=_blank>2017 IDF实践指南:糖尿病和斋月</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E7%B3%96%E5%B0%BF%E7%97%85" target=_blank>有关糖尿病更多指南</a></ul>, tagList=[TagDto(tagId=12164, tagName=达格列净), TagDto(tagId=65, tagName=治疗), TagDto(tagId=5966, tagName=2型), TagDto(tagId=216, tagName=糖尿病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=4, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4354, appHits=281, showAppHits=9, pcHits=2829, showPcHits=2175, likes=110, shares=7, comments=4, approvalStatus=1, publishedTime=Thu Apr 27 09:04:16 CST 2017, publishedTimeString=2017-04-27, pcVisible=1, appVisible=1, editorId=5295982, editor=yanqin, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=yanqin, createdTime=Thu Apr 27 09:04:16 CST 2017, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 13:47:32 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017 共识声明:临床应用达格列净治疗2型糖尿病)])
2017 共识声明:临床应用达格列净治疗2型糖尿病
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=192807, encodeId=41c819280ea9, content=如何阅读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yApDfGjfGDIzdu89m5XtUGZ8H0KuxSNdbgX6JqFriaFHcJSLISLJJRAxlRooG8uyJakZ6lUGnicGAlgX6JB2iavmwOMnIYiblMGX8/0, createdBy=69e91993560, createdName=量力而行, createdTime=Tue May 02 09:23:12 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191330, encodeId=456c191330e0, content=一起来讨论吧, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/03/04d9b9f3fcb2c24e0534b0a7de83c72e.jpg, createdBy=75672052751, createdName=月吟凤歌, createdTime=Fri Apr 28 07:12:43 CST 2017, time=2017-04-28, status=1, ipAttribution=)]
    2017-05-02 量力而行

    如何阅读

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=192807, encodeId=41c819280ea9, content=如何阅读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yApDfGjfGDIzdu89m5XtUGZ8H0KuxSNdbgX6JqFriaFHcJSLISLJJRAxlRooG8uyJakZ6lUGnicGAlgX6JB2iavmwOMnIYiblMGX8/0, createdBy=69e91993560, createdName=量力而行, createdTime=Tue May 02 09:23:12 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191330, encodeId=456c191330e0, content=一起来讨论吧, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/03/04d9b9f3fcb2c24e0534b0a7de83c72e.jpg, createdBy=75672052751, createdName=月吟凤歌, createdTime=Fri Apr 28 07:12:43 CST 2017, time=2017-04-28, status=1, ipAttribution=)]
    2017-04-28 月吟凤歌

    一起来讨论吧

    0